- Raised $1.7M funding round led by VLX Ventures, May 2025
About
Sakura Bio has developed an off-the-shelf, naïve PBMC-derived allogeneic T-cell therapy to fight cancer — in particular, acute myeloid leukemia.
The company's platform focuses on creating super-activated killer cells, an allogenic T-cell therapy produced via a simple, relatively short manipulation of naïve PBMCs.
Sakura Bio's lead product, Super Activated Killer T-cell (SAK-T), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. In contrast to other T-cell-based products, such as CAR-T, SAK-T cells have a high safety profile, with no graft-versus-host disease, and can be developed as an off-the-shelf T-cell product.
SAK-T's outstanding killing properties of leukemic cells led Sakura to choose acute myeloid leukemia as its first-in-human indication for SAK therapy.
Funding history · 1 round · $1.7M total
Q&A
- What is Sakura Bio's primary focus?
- Sakura Bio focuses on developing an off-the-shelf, naïve PBMC-derived allogeneic T-cell therapy to combat cancer, specifically acute myeloid leukemia.
- What is Sakura Bio's lead product?
- Sakura Bio's lead product is Super Activated Killer T-cell (SAK-T), a unique T-cell population designed for superior anti-tumor cytotoxic activity without toxicity to healthy tissue.
- What is the safety profile of SAK-T cells compared to other T-cell products?
- SAK-T cells have a high safety profile, with no graft-versus-host disease, distinguishing them from other T-cell-based products like CAR-T.
- What is the first-in-human indication for SAK therapy?
- Due to SAK-T's killing properties of leukemic cells, Sakura Bio has chosen acute myeloid leukemia as its first-in-human indication for SAK therapy.
- When was Sakura Bio founded?
- Sakura Bio was founded in October 2022.
- How many employees does Sakura Bio currently have?
- Sakura Bio has 1-10 employees.
- What is Sakura Bio's current funding stage?
- Sakura Bio is currently in the Pre-Seed funding stage.
- What is the total amount of funding raised by Sakura Bio?
- Sakura Bio has raised a total of $1,700,000.
- When did Sakura Bio complete its last funding round and who were the lead investors?
- In May 2025, Sakura Bio completed a funding round with.
Team · 1
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | sakurabio.com/ |
|---|---|
| linkedin.com/company/86832778 |
Identifiers & details
| Founded | 2022-10 |
|---|---|
| Employees (exact) | 5 |
Radar intelligence
Web history (Wayback)
| Domain | sakurabio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|